Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 10, 2021
Share
Universal Vision Biotechnology Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 614.770 million compared to TWD 483.991 million a year ago. Operating income was TWD 165.377 million compared to TWD 141.174 million a year ago. Net income was TWD 127.504 million compared to TWD 114.989 million a year ago. Basic earnings per share from continuing operations was TWD 1.67 compared to TWD 1.51 a year ago. For the half year, sales was TWD 1,225.045 million compared to TWD 878.788 million a year ago. Operating income was TWD 358.097 million compared to TWD 242.283 million a year ago. Net income was TWD 276.939 million compared to TWD 204.348 million a year ago. Basic earnings per share from continuing operations was TWD 3.64 compared to TWD 2.68 a year ago.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 
